Nope, they had two previously good trials with 0.3mg dosage: Phase 1/2 and Phase 2a. The higher dosage during the most recent clinical evaluation failed to prove meaningful results.Hi all.
So does this mean OTO-413 failed completely? Or is it just the higher dosing that did not show good results?
@Brian Newman, I think both Otonomy's products probably worked but to such a small degree that placebo was too strong. I doubt Frequency Therapeutics will show significant improvement, but who knows hey?Literally hilarious. OTO-413 probably works, there are compounds that can help us and give us our lives back but we won't see them ever. I can't explain my anger and disappointment. They had positive results for lower doses but screwed up OTO-313 and high doses of OTO-413.
Frequency Therapeutics will probably fail too sending the company under.
Sorry for the pessimism but this hearing stuff is no joke and I think it is one of the worst things you could ever get if you have it severe enough. I promise they will have the cure for cancer before any kind of hearing restoration drug that comes out. Probably 20-30 years unless we're lucky. Well folks, I hope everybody enjoys their lives if they can leave their home. I'll be in my room rotting for the next few decades.
Nothing's impossible, I won't have my hopes up though. I pray more than anything we get something soon.@Brian Newman, I think both Otonomy's products probably worked but to such a small degree that placebo was too strong. I doubt Frequency Therapeutics will show significant improvement, but who knows hey?
Yes, there is the potential for a buyer to take a chance with these two technologies. Can you imagine a combined gel that stimulated hair cell repair/replacement as well as re-synapsing?We previously fantasised about one company owning the knowledge / technology of both Otonomy and Frequency Therapeutics. The slow release gel, if I'm not mistaken. That is now on the table...
Possibly Syncona. Syncona acquiring AGTC (Applied Genetic Technologies Corporation) who is in partnership with Otonomy because of their gene therapy research might be interested in Frequency Therapeutics too.Yes, there is the potential for a buyer to take a chance with these two technologies. Can you imagine a combined gel that stimulated hair cell repair/replacement as well as re-synapsing?
Anyone know someone who would take on this challenge?
The stock price more than doubled already today so potentially a deal has been made.Possibly Syncona. Syncona acquiring AGTC (Applied Genetic Technologies Corporation) who is in partnership with Otonomy because of their gene therapy research might be interested in Frequency Therapeutics too.
Yay, it happened Looks like the OTIC stock was a pump and dump short squeeze, but happy to have the offer go through.The stock price more than doubled already today so potentially a deal has been made.
BUY THE DIP.Otonomy is liquidating all assets and paying stockholders any remaining revenue. Keep or dump stock?
What a shame, OTO-413 seems to be effective at synapse regrowth. Hopefully someone like Frequency Therapeutics or another well known company can buy it and start clinical trials.I wonder where their clinical trialed drugs would end up at?
I never invested in OTIC other than being personally hopeful like we all were, but I'm starting to think that even if their latest trial was successful, they'd still go down the same path and liquidate. I feel that was their goal from the get go to try and raise their share value without actually getting a drug out to market.Otonomy is liquidating all assets and paying stockholders any remaining revenue. Keep or dump stock?
Yep, they seem to want to get it all at once (risk a grand slam when you can for sure get someone on first base). If they got something that works just a little, that's a great starter in a field where we still use antiquated tech such as hearing aids and steroid shots, and nothing else really.What a shame, OTO-413 seems to be effective at synapse regrowth. Hopefully someone like Frequency Therapeutics or another well known company can buy it and start clinical trials.
This is what happens when companies try and increase the dosage or do multiple dosing in quick succession.
While it could potentially be a good pairing for FREQ to pick up some of the OTIC patents, FREQ doesn't have the cash pile to afford it right now. With their own current clinical plans, FREQ will be out of money sometime in 2024 if they get no further milestone payments or raise capital via a stock offering.I'm hoping someone like Frequency Therapeutics picks them up to diversify their lineup and cover both bases (hearing cells and synaptopathy). I still do believe in the product as a first gen hearing treatment.
If the OTO-413 trial demonstrated more convincing positive outcomes, they would certainly not have gone down the same path. They would have options to continue to fund development that they don't have today. It's possible they would have considered an acquisition prior to a successful OTO-413 trial, but dissolving and cashing out would have been unlikely.I'm starting to think that even if their latest trial was successful, they'd still go down the same path and liquidate. I feel that was their goal from the get go to try and raise their share value without actually getting a drug out to market.
Won't happen. They don't have the cash and the OTO-413 IP doesn't fit their PCA approach model.I'm hoping someone like Frequency Therapeutics picks them up to diversify their lineup and cover both bases (hearing cells and synaptopathy). I still do believe in the product as a first gen hearing treatment.
Most people habituate so they don't actually hear their tinnitus 24/7.So OTO-413 is also out of the equation as a potential remedy for us sufferers?
Is Dr. Shore's device really our only hope of ever hearing silence again?
They're not officially closing up shop yet though. But it does look dire. I still think another big biotech firm might acquire them but the whole situation with the finances is dicey right now with interest rates so high, so maybe late next year when rates start to come down again.Wel, it's been real Otonomy but at least your company cared enough to at least
try, so therefore
feels like the ending of an era though. All the ups and downs finally coming to a sad ending.
I still have hope with OTO-413. Only reason for their failure was them increasing the dosage. I wonder if they had kept it at 0.3 mg, would their trial have succeeded to the point where it comes out in the market? I'm not sure. We would have known if there was any benefit or not if they had tested it with at least 100 people or more in their Phase 2 trial with 0.3 mg.It seems the only thing Otonomy is able to clearly demonstrate is their inability to get their drugs over the finish line. I'm glad I only lost a few hundred dollars. What I haven't lost is hope. Thank you everyone who has contributed time and knowledge to this thread and the research threads in general.
BDNF has been shown to be beneficial for treating other issues like strokes. I think that intratympanic injection for this in some form might be possible in the near future, because of how important it is for the human body. I'm sure everything will work out.I still have hope with OTO-413. Only reason for their failure was them increasing the dosage. I wonder if they had kept it at 0.3 mg, would their trial have succeeded to the point where it comes out in the market? I'm not sure. We would have known if there was any benefit or not if they had tested it with at least 100 people or more in their Phase 2 trial with 0.3 mg.
I hope they find a potential buyer who can start and finish off the OTO-413 trials ASAP. I don't really want them to delay too long as there was already a benefit with the 0.3 mg dose.BDNF has been shown to be beneficial for treating other issues like strokes. I think that intratympanic injection for this in some form might be possible in the near future, because of how important it is for the human body. I'm sure everything will work out.